<DOC>
	<DOCNO>NCT02972983</DOCNO>
	<brief_summary>The purpose study examine effect second antibiotic , daptomycin , combination beta lactam antibiotic treat bloodstream infection cause methicillin-susceptible S. aureus .</brief_summary>
	<brief_title>Daptomycin Adjunctive Therapy Staphylococcus Aureus Bacteremia</brief_title>
	<detailed_description>When patient blood infection methicillin-susceptible S. aureus , treat usual standard care , include abeta-lactam antibiotic , blood test daily presence infection test negative , well ultrasound heart rule infection heart valve , well catheter remove ( possible ) ensure adequate control infection . This study involve add second antibiotic , daptomycin , treatment regimen half patient enrol study . Daptomycin approve Health Canada treat blood infection due Staphylococcus aureus . It currently use combination beta-lactam infection insufficient evidence benefit justify cost . The study participant receive additional daily iv therapy consist either daptomycin placebo total five day admit hospital . During time , participant continue blood drawn ass presence bacteria . The participant ' liver muscle enzyme also measure first fifth day therapy test potential side effect daptomycin .</detailed_description>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<criteria>Patient methicillin susceptible Staphylococcus aureus bacteremia . Underlying terminal illness Significant contraindication betalactam therapy ( i.e . severe allergy , severe adverse drug reaction ) Expected death 5 day Microbiologically confirm need concomitant VANCOMYCIN DAPTOMYCIN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Staphylococcus aureus</keyword>
	<keyword>Bacteremia</keyword>
	<keyword>Daptomycin</keyword>
</DOC>